Crossmark

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Crossref DOI link: https://doi.org/10.1186/s40880-016-0086-2

Published Online: 2016-03-21

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Jiang-Yong

Yu, Si-Fan

Wang, Shu-Hang

Bai, Hua

Zhao, Jun

An, Tong-Tong

Duan, Jian-Chun

Wang, Jie
Funding

Funding for this research was provided by:

Project supported by the National Natural Sciences Foundation Key Program ([81330062])

Education Ministry Innovative Research Team Program ([IRT13003])

Peking University-Tsinghua University Joint Center for Life Sciences Clinical Investigator; National High Technology Research and Development Program 863 ([SS2015AA020403])

Beijing Technology Project ([Z141100000214013])